Results 91 to 100 of about 20,923 (159)

Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin. [PDF]

Biomedicines
Habeos EE, Markantes GK, Parthymou A, Dimitropoulos K, Habeos GI, Papasotiriou M, Marangos M, Chartoumpekis DV.   +7 more
europepmc   +1 more source

Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Meng Z, Wu H, Miao Y, Qi W, Sha M.
europepmc   +1 more source

Hyperglycemia in Diabetes Drives Hepatic Fibrosis Through the Non-Enzymatic Function of HK2 and AGEs-mediated Matrix Stiffening. [PDF]

Int J Biol Sci
Huang C, Qian J, Zhang L, Liu Y, Zhou Q, Li J, Zhao Y, Yu H, Zhang Y, Huang J, Li M, Ren Z, Xu Z, Liu R, Wang X, Chen J, Cui J, Yang Y.   +17 more
europepmc   +1 more source

Empagliflozin inhibits the apoptosis of pancreatic β-cells through amelioration of endoplasmic reticulum (ER) stress. [PDF]

Metabol Open
Nasiri-Ansari N, Randeva MS, Flessa CM, Kyrou I, Lembessis P, Kiaris H, Chondrogianni ME, Dalamaga M, Papavassiliou AG, Randeva HS, Kassi E.   +10 more
europepmc   +1 more source

Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease. [PDF]

Diabetes Obes Metab
Beernink JM, Laverman GD, Heerspink HJL.
europepmc   +1 more source

Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells. [PDF]

J Cancer
Lee YH, Chen PN, Hsieh YH, Chu YC, Chen LJ, Lin CY, Yang SF, Chang HR.   +7 more
europepmc   +1 more source

Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies. [PDF]

Front Pharmacol
Ali LS, Mostafa MO, Alsharayiah D, Elkholy MA, Ahmed KA, El-Mansy AA, Sharfeldeen AERM, El Wakeel G, Badawy AA, Sulaiman AH, Ali EI, Alenazi MS, Alruwaili MM, Hamza E, Eldesoqui M.   +14 more
europepmc   +1 more source

Empagliflozin in GSD-Ib: Long-term safety and sustained recovery of neutrophil function including NET formation. [PDF]

Mol Genet Metab Rep
Mathis D, Felser A, Hochuli M, Ballhausen D, Boros-Majewska J, Bourquin C, Simon HU, Gautschi M, Stojkov D.   +8 more
europepmc   +1 more source

SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications. [PDF]

Mol Biomed
Zheng XT, Xie HY, Wang XH, Zhao Y, Yang JY, Liu YX, Yuan XL, Tang HF, Jiang ZS, Hu HJ.   +9 more
europepmc   +1 more source

Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes: A 6-month observational study. [PDF]

Medicine (Baltimore)
Nguyen MQD, Tran KDD, Tran SK.
europepmc   +1 more source